HFpEF Now Tops 50% of All Heart Failure Cases — What Works in 2026

HFpEF has quietly overtaken its better-known counterpart — heart failure with reduced ejection fraction (HFrEF) — to become the dominant form of heart failure globally. This 2026 systematic review, published in Vascular Health and Risk Management, synthesizes 83 studies (22 RCTs, 38 observational cohorts, and 23 systematic reviews or meta-analyses) drawn from PubMed, Scopus, Web of Science, and the Cochrane Library, covering publications from January 2015 through June 2025. The review applies the Newcastle–Ottawa Scale for observational studies, the Cochrane Risk of Bias tool for RCTs, and AMSTAR 2 for systematic reviews, providing methodological rigor rarely seen in narrative summaries of this syndrome.

Epidemiologically, HFpEF now represents more than 50% of all heart failure diagnoses worldwide. In European cohorts it accounts for 50–55% of cases; in the United States, the Get With The Guidelines–Heart Failure (GWTG-HF) registry places the figure at 47–50%. Older women bear the greatest burden, with incidence rising sharply after age 65. East Asian urban populations show 30–45% prevalence, again skewed toward older female patients. Modifiable comorbidities — hypertension, type 2 diabetes, obesity, and atrial fibrillation — collectively drive a systemic pro-inflammatory milieu that triggers coronary microvascular dysfunction, progressive myocardial fibrosis via TGF-β and MMP dysregulation, and concentric left ventricular hypertrophy. Valvular heart disease (moderate or greater aortic stenosis or regurgitation) is present in roughly 6–8% of HFpEF cases, further accelerating deterioration.

Diagnosis remains the field's Achilles heel. Current guidelines require LVEF ≥50% plus objective evidence of structural abnormalities and elevated LV filling pressures. NT-proBNP is the cornerstone biomarker, yet its sensitivity is blunted by obesity, renal impairment, and sex differences. Emerging biomarkers — sST2, galectin-3, and GDF-15 — improve diagnostic precision and risk stratification, though none have been fully integrated into routine clinical algorithms. Echocardiographic advances, particularly tissue Doppler and speckle-tracking strain imaging, have substantially improved non-invasive detection of diastolic dysfunction.

On the therapeutic front, SGLT2 inhibitors represent the most robustly validated pharmacological class. The FINEARTS-HF trial demonstrated that finerenone, a nonsteroidal mineralocorticoid receptor antagonist, reduced worsening heart failure events and cardiovascular mortality in HFmrEF/HFpEF patients, marking a significant addition beyond SGLT2 inhibitor therapy. In obesity-associated HFpEF, the STEP-HFpEF program showed that semaglutide produced clinically meaningful improvements in symptoms, exercise capacity, and body weight, while the SUMMIT trial confirmed tirzepatide's benefits on composite cardiovascular and heart failure outcomes — both agents performing best in cardiometabolic phenotypes.

The review underscores that HFpEF is not a monolithic disease but a heterogeneous clinical syndrome encompassing at least three overlapping phenotypic subsets: inflammatory, metabolic, and fibrotic. Each carries distinct pathobiological signatures and differential therapeutic responsiveness. The authors argue that phenotype-guided treatment algorithms — rather than one-size-fits-all protocols — are essential. Multidisciplinary care integrating cardiologists, endocrinologists, nephrologists, and rehabilitation specialists is presented as the current standard of practice. The authors call for real-world evidence to validate trial findings and for updated international guidelines to formally incorporate finerenone and GLP-1/GIP receptor agonists.